Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508532 · ClinicalTrials.gov registry record · Phase 1
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
A Phase 1 study, sponsored by Blueprint Medicines Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
NCT02508532: Completed Phase 1 study, sponsored by Blueprint Medicines Corporation.
NCT02508532 is a Phase 1 study that has completed, run by Blueprint Medicines Corporation. The registered enrollment target is 250 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (317% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02508532, a Phase 1 study, has completed, sponsored by Blueprint Medicines Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).
Primary Outcome
Patients with event(s) of dose-limiting toxicity
Interventions
- DRUG Avapritinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2015-08 |
| Est. Completion | 2021-06-03 |
| Phase | Phase 1 |
What the finished NCT02508532 record still lists
NCT02508532 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (317% higher).
The record links to 0 conditions, and to 1 intervention - of which Avapritinib is the first listed.
NCT02508532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02508532 about?
NCT02508532 is a clinical study titled "(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors". This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or...
What is the current status of trial NCT02508532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2015-08. Estimated completion is 2021-06-03.
What interventions are being tested in trial NCT02508532?
The interventions under investigation include: Avapritinib (DRUG).
Who is sponsoring clinical trial NCT02508532?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02508532's enrollment target sits among peer trials
250 173rd of 2000 higher than 1,816 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia